NYMOX PHARMACEUTICAL CORP Research And Development Expense

Quick Answer

NYMOX PHARMACEUTICAL CORP reported Research And Development Expense of $3.28 million for the year ending 2024.

  • NYMOX PHARMACEUTICAL CORP showed a decrease of -17.9% in Research And Development Expense from 2023 to 2024.
  • This data is from NYMOX PHARMACEUTICAL CORP's annual report (Form 10-K), filed with the SEC on June 3, 2025.
  • XBRL data for this metric is available from 2015 to 2024 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 10 years of available data (2015 to 2024), NYMOX PHARMACEUTICAL CORP's Research And Development Expense has declined by 62.1%.
  • Historical annual values: Fiscal year 2024: $3.28 million | Fiscal year 2023: $3.99 million | Fiscal year 2022: $3.77 million | Fiscal year 2021: $6.66 million | Fiscal year 2020: $8.12 million | Fiscal year 2019: $7.38 million | Fiscal year 2018: $6.68 million | Fiscal year 2017: $7.87 million | Fiscal year 2016: $6.80 million | Fiscal year 2015: $8.65 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: